Par Pharmaceutical is suing the U.S. Food and Drug Administration in D.C. federal court over its revoked 180-day exclusivity period for a generic gout drug, saying the agency incorrectly deemed its patent certifications faulty.
Depomed Inc. won a major ruling when a New Jersey federal judge said patents relating to its painkiller drug Nucynta are valid and that several generic drugmakers have infringed claims on the patents, giving the pharmaceutical giant a market lock on Nucynta products through 2025.
A Maryland federal judge has ruled that TWi Pharmaceuticals Inc. may recover $12.7 million from bonds that Par Pharmaceutical Inc. and Alkermes Pharma Ireland Ltd. posted in a case in which the court twice invalidated the asserted claims of their patent covering a weight loss-combating drug.
French pharmaceutical giant Sanofi-Aventis US Inc. sued Merck & Co. Inc.'s overseas unit in Delaware federal court , alleging the rival pharmaceutical company developed a diabetes drug that infringes 10 patents for its top-selling Lantus insulin product and its SoloStar injection pen.
Roxane Laboratories Inc. blasted a New Jersey federal judge’s ruling that a generic calcium acetate drug from Hetero Drugs Ltd. units likely doesn’t infringe Roxane kidney medication PhosLo and should therefore be allowed on the market, explaining to a Federal Circuit panel that the difference in capsule size between the two drugs is insignificant in view of the patent claims.
Pfizer Inc. has reached a settlement with AntiCancer Inc. to resolve claims the drug giant unlawfully terminated a patent licensing agreement for AntiCancer's research technology following Pfizer's 2009 merger with fellow pharmaceutical behemoth Wyeth.